Stock Events

Stock Events

Janux Therapeutics 

$15.18
0
+$0.24+1.61% Today

Statistics

Day High
15.18
Day Low
15.04
52W High
-
52W Low
-
Volume
17
Avg. Volume
-
Mkt Cap
923.43M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2025
Q4 2025
Next
-0.62
-0.55
-0.47
-0.39
Expected EPS
-0.570154
Actual EPS
N/A

Financials

-1,136.25%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
20MRevenue
-227.25MNet Income

Analyst Ratings

$46.38Average Price Target
The highest estimate is 100.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
78%
Hold
22%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow JANX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. is a global healthcare company that operates in the same oncology space, competing with Janux Therapeutics in developing cancer treatments.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines in areas including oncology, competing directly with Janux Therapeutics.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a biotechnology company focused on human therapeutics, including oncology, which puts it in direct competition with Janux Therapeutics.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, Inc. focuses on antiviral drugs and cancer therapies, making it a competitor in the oncology sector alongside Janux Therapeutics.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. is a global biopharmaceutical company with a strong emphasis on oncology, competing with Janux Therapeutics in cancer drug development.
Roche
RHHBY
Mkt Cap321.08B
Roche Holding AG is a major player in the pharmaceutical and diagnostics world, with a significant focus on oncology, competing with Janux Therapeutics.
Novartis
NVS
Mkt Cap297.32B
Novartis AG focuses on patented medicines, including those for cancer, making it a direct competitor to Janux Therapeutics in the oncology field.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca PLC is a global, science-led biopharmaceutical business that operates in the same therapeutic areas as Janux Therapeutics, including oncology.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, Inc. is known for its innovation in biotechnology, including oncology, competing with Janux Therapeutics in developing cancer treatments.

About

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Show more...
CEO
ISIN
US47103J1051

Listings

XNAS
US
JANX
BOATS
BOATS
JANX.BOATS

0 Comments

Share your thoughts

FAQ

What is Janux Therapeutics stock price today?▼
The current price of JANX.BOATS is $15.18 USD — it has increased by +1.61% in the past 24 hours. Watch Janux Therapeutics stock price performance more closely on the chart.
What is Janux Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Janux Therapeutics stocks are traded under the ticker JANX.BOATS.
What is Janux Therapeutics market cap?▼
Today Janux Therapeutics has the market capitalization of 923.43M
When is the next Janux Therapeutics earnings date?▼
Janux Therapeutics is going to release the next earnings report on May 12, 2026.
What were Janux Therapeutics earnings last quarter?▼
JANX.BOATS earnings for the last quarter are -0.51 USD per share, whereas the estimation was -0.62 USD resulting in a +18.38% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Janux Therapeutics revenue for the last year?▼
Janux Therapeutics revenue for the last year amounts to 20M USD.
What is Janux Therapeutics net income for the last year?▼
JANX.BOATS net income for the last year is -227.25M USD.
When did Janux Therapeutics complete a stock split?▼
Janux Therapeutics has not had any recent stock splits.